Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/812
Title: Efficacy of sotrastaurin plus tacrolimus after de novo kidney transplantation: randomized, phase II trial results.
Epworth Authors: Cohney, Solomon (Shlomo)
Other Authors: Russ, G.
Tedesco-Silva, H.
Kuypers, D.
Langer, R.
Witzke, O.
Eris, J.
Sommerer, C.
Tufeveson, G.
Woodle, E.
Gill, J.
Ng, J.
Klupp, J.
Chodoff, K.
Keywords: Biopsy
Dose-Response Relationship
Glomerular Filtration Rate
Graft Rejection
Immunosuppressive Agents
Pyrroles
Kidney Transplantation
Quinazolines
Tacrolimus
Immunosuppressive Agents
Sotrastaurin
T Cell Activation
Kinase C Inhibition
Gastrointestinal
Leukopenia
UroRenal, Vascular Clinical Institute, Epworth HealthCare, Victoria, Australia
Department of Gastroenterology, Epworth HealthCare, Victoria, Australia.
Issue Date: Jul-2013
Publisher: Wiley Online Library
Citation: 2013 Jul;13(7):p.1746-56.
Abstract: Sotrastaurin, a novel immunosuppressant, blocks early T cell activation through protein kinase C inhibition. Efficacy and safety of sotrastaurin with tacrolimus were assessed in a dose-ranging non-inferiority study in renal transplant recipients. A total of 298 patients were randomized 1:1:1:1 to receive sotrastaurin 100 (n = 77; discontinued in December 2011) or 200 mg (n = 73) b.i.d. plus standard tacrolimus (sTAC; 5-12 ng/mL), sotrastaurin 300 mg (n = 75) b.i.d. plus reduced tacrolimus (rTAC; 2-5 ng/mL) or enteric-coated mycophenolic acid (MPA) plus sTAC (n = 73); all patients received basiliximab and corticosteroids. Composite efficacy failure (treated biopsy-proven acute rejection ≥ grade IA, graft loss, death or loss to follow up) rates at Month 12 were 18.8%, 12.4%, 10.9% and 14.0% for the sotrastaurin 100, 200 and 300 mg, and MPA groups, respectively. The median estimated glomerular filtration rates were 55.7, 53.3, 64.9 and 59.2 mL/min, respectively. Mean heart rates were faster with higher sotrastaurin doses and discontinuations due to adverse events and gastrointestinal adverse events were more common. Fewer patients in the sotrastaurin groups experienced leukopenia than in the MPA group (1.3-5.5% vs. 16.5%). Sotrastaurin 200 and 300 mg had comparable efficacy to MPA in prevention of rejection with no significant difference in renal function between the groups.
URI: http://hdl.handle.net/11434/812
DOI: 10.1111/ajt.12251
PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/23668931
ISSN: 1600-6143
‎1600-6135
Journal Title: American Journal of Transplantation
Type: Journal Article
Affiliated Organisations: Department of Nephrology and Transplantation, Central Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Faculty of Health Sciences, University of Adelaide, North Terrace, Adelaide, SA, Australia
Type of Clinical Study or Trial: Randomized Controlled Clinical Trial
Appears in Collections:UroRenal, Vascular

Files in This Item:
There are no files associated with this item.


Items in EKB are protected by copyright, with all rights reserved, unless otherwise indicated.